BIO Comments on FDA Draft Guidance on Formal Meetings Between the FDA and Sponsors or Applicants of Prescription Drug User Fee Act Products
March 27, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products.
The Prescription Drug User Fee Act (PDUFA) meeting structure fosters robust communication between the FDA and industry and promotes biomedical innovation. Formal, face-to-face meetings – along with other types of communication like well-written responses, phone calls, and emails – are critical for aligning on complex scientific matters throughout the drug development process.
With clarifications, this guidance could be a helpful tool for sponsors to engage in more productive discussions with the FDA. BIO requests clarifications on surrogate endpoint/biomarker Type C meetings, background package contents, whether FDA welcomes discussion of emerging data sources (patient experience data, novel trial designs, real-world evidence), preliminary responses to sponsors, and meeting timelines, among other issues.
Download Full Comments Below
BIO Letter Formal Meetings Between The Food And Drug Administration And Sponsors FDA–2017-D-6530
Dear Colleagues,This month marks my one-year anniversary as BIO’s CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request forComments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Prescription Drug User Fee Act Products.
The Prescription Drug User Fee Act (PDUFA) meeting structure fosters robust communication between the FDA and industry and promotes biomedical innovation. Formal, face-to-face meetings – along with other types of communication like well-written responses, phone calls, and emails – are critical for aligning on complex scientific matters throughout the drug development process.
With clarifications, this guidance could be a helpful tool for sponsors to engage in more productive discussions with the FDA. BIO requests clarifications on surrogate endpoint/biomarker Type C meetings, background package contents, whether FDA welcomes discussion of emerging data sources (patient experience data, novel trial designs, real-world evidence), preliminary responses to sponsors, and meeting timelines, among other issues.